ImmunityBio (IBRX)
(Delayed Data from NSDQ)
$3.52 USD
+0.04 (1.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.52 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum F VGM
Price, Consensus and EPS Surprise
IBRX 3.52 +0.04(1.15%)
Will IBRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IBRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IBRX
Company News for Aug 13, 2024
ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates
IBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
Other News for IBRX
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA? and Checkpoint Immunotherapy at World Conference on Lung Cancer
Amid Major Threats, Merck Stock Is A Sell
CG Oncology: Promising Data, But Looks Expensive
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session